PRA Health Sciences, Inc

Prices are adjusted according to historical splits.

PRA Health Sciences, Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$6.769 billion
Book Value:
Revenue TTM:
$3.095 billion
Operating Margin TTM:
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

PRA Health Sciences, Inc had its IPO on 2014-11-13 under the ticker symbol PRAH.

The company operates in the sector and industry. PRA Health Sciences, Inc has a staff strength of 17,500 employees.

Stock update

Shares of PRA Health Sciences, Inc opened at $165.21 at the start of the last trading session i.e. 2021-07-01.

The stocks traded within a range of $165.21 - $165.21, and closed at $165.21.

This is a 0% increase from the previous day's closing price.

A total volume of 57 shares were traded at the close of the day’s session.

In the last one week, shares of PRA Health Sciences, Inc have slipped by -1.07%.

PRA Health Sciences, Inc's Key Ratios

PRA Health Sciences, Inc has a market cap of $6.769 billion, indicating a price to book ratio of 5.2631 and a price to sales ratio of 2.0115.

In the last 12-months PRA Health Sciences, Inc’s revenue was $3.095 billion with a gross profit of $0.000 billion and an EBITDA of $0.430 billion. The EBITDA ratio measures PRA Health Sciences, Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, PRA Health Sciences, Inc’s operating margin was 9.92% while its return on assets stood at 5.36% with a return of equity of 18.22%.

In Q2, PRA Health Sciences, Inc’s quarterly earnings growth was a negative -64.6% while revenue growth was a negative 4.4%.

PRA Health Sciences, Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $3.273 per share while it has a forward price to earnings multiple of 16.9779 and a PEG multiple of 1.9315. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PRA Health Sciences, Inc’s profitability.

PRA Health Sciences, Inc stock is trading at a EV to sales ratio of 2.4132 and a EV to EBITDA ratio of 17.689. Its price to sales ratio in the trailing 12-months stood at 2.0115.

PRA Health Sciences, Inc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio

PRA Health Sciences, Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

PRA Health Sciences, Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

PRA Health Sciences, Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, PRA Health Sciences, Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, PRA Health Sciences, Inc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

PRA Health Sciences, Inc stock is currently trading at $165.21 per share. It touched a 52-week high of $113.315 and a 52-week low of $113.315. Analysts tracking the stock have a 12-month average target price of $113.62.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 3.42 indicating a short percent outstanding of 2%.

Around 24.7% of the company’s stock are held by insiders while 9986.6% are held by institutions.

Frequently Asked Questions About PRA Health Sciences, Inc

The stock symbol (also called stock or share ticker) of PRA Health Sciences, Inc is PRAH

The IPO of PRA Health Sciences, Inc took place on 2014-11-13

Similar Industry Stocks ()

Last Price
Copart Inc (CPRT)
Stellantis NV (STLA)
iSun Inc (ISUN)

Most Active

Last Price
Apple Inc (AAPL)

Top Gainers

Last Price

Top Losers

Last Price
Air T, Inc (AIRTW)


PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, as well as bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services that clients to access and analyze Symphony Health and integrated third-party data. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardiometabolic, and infectious diseases. The company has a partnership with The Leukemia & Lymphoma Society to launch a clinical trial for developing treatments for children with relapsed acute leukemia. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.


4130 ParkLake Avenue, Raleigh, NC, United States, 27612